CellWell record HH-338111
Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [14C]Xevinapant, a Potent, Oral, Small-Molecule IAP Inhibitor
Annick Menetrey; Valérie Nicolas-Metral; Marie-Claude Roubaudi-Fraschini; Tri Tat; Yuan Zhao; Yulia Vugmeyster; Karthik Venkatakrishnan; Felix Rohdich; Holger Scheible
2026
In plain language
Xevinapant demonstrated 57.8% oral bioavailability with rapid absorption and predominantly fecal excretion of metabolites in healthy adults.
- Evidence
- Established
- Design
- Clinical trial
Cite this record: https://thecellwell.org/studies/HH-338111
Produced by the CellWell Research Engine, custom software owned and operated by CellWell. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.